UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 50 filers reported holding UNIQURE NV in Q3 2016. The put-call ratio across all filers is 0.15 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $286,517 | +138.1% | 42,700 | +306.7% | 0.00% | – |
| Q2 2023 | $120,330 | -89.9% | 10,500 | -82.3% | 0.00% | -100.0% |
| Q1 2023 | $1,194,624 | +466.2% | 59,316 | +423.4% | 0.00% | +200.0% |
| Q2 2022 | $211,000 | -10.2% | 11,333 | +62.2% | 0.00% | 0.0% |
| Q1 2021 | $235,000 | -30.5% | 6,985 | -6.7% | 0.00% | -50.0% |
| Q2 2020 | $338,000 | -71.7% | 7,484 | -70.2% | 0.00% | -80.0% |
| Q1 2020 | $1,193,000 | +91.5% | 25,136 | +188.9% | 0.01% | +150.0% |
| Q4 2019 | $623,000 | +43.9% | 8,700 | -21.0% | 0.00% | 0.0% |
| Q3 2019 | $433,000 | -69.3% | 11,009 | -39.0% | 0.00% | -69.2% |
| Q2 2019 | $1,410,000 | +190.1% | 18,044 | +121.8% | 0.01% | +333.3% |
| Q1 2019 | $486,000 | +3371.4% | 8,136 | +328.2% | 0.00% | – |
| Q2 2016 | $14,000 | 0.0% | 1,900 | +58.3% | 0.00% | – |
| Q1 2016 | $14,000 | – | 1,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 841,471 | $15,786,000 | 5.69% |
| Nantahala Capital Management | 2,901,929 | $54,440,000 | 3.52% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 544,500 | $10,209,000 | 3.27% |
| 683 Capital Management, LLC | 1,373,600 | $25,768,000 | 1.99% |
| PFM Health Sciences, LP | 2,393,311 | $44,899,000 | 1.62% |
| Integral Health Asset Management, LLC | 433,000 | $8,123,000 | 1.58% |
| Privium Fund Management B.V. | 238,998 | $4,283,000 | 1.56% |
| Nantahala Capital Management | 1,000,000 | $18,760,000 | 1.21% |
| Henry James International Management Inc. | 89,469 | $1,678,000 | 0.94% |
| Altium Capital Management LP | 105,000 | $1,970,000 | 0.72% |